Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154140 | 0.91 | HTR4 (0.45) | FLT3CHEK1MAPK1OPRK1RPS6KB1 | |
| SCHEMBL6153679 | 0.85 | HTR4 (0.48) | FLT3RPS6KB1SYKAURKA | |
| SCHEMBL6154287 | 0.85 | PARP15 (0.55) | FLT3SYK | |
| Hydrochloric Acid SCHEMBL29032399 | 0.81 | DRD4 (0.43) | CHEK1MAPK1OPRK1ALOX15 | |
| SCHEMBL6153341 | 0.79 | KIT (0.60) | FLT3SYK | |
| SCHEMBL6153579 | 0.79 | KIT (0.60) | FLT3SYK | |
| SCHEMBL6153345 | 0.79 | KIT (0.60) | FLT3SYK | |
| SCHEMBL6154274 | 0.79 | HTR4 (0.50) | FLT3SYK | |
| SCHEMBL6153322 | 0.78 | FLT3 (0.47) | FLT3SYKAURKA | |
| SCHEMBL6154491 | 0.78 | KIT (0.47) | FLT3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | FLT3 2536/4885CHEK1 2194/4885MAPK1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.